Journal ArticleOPEN ACCESS

Enzalutamide: new second‐line treatment for prostate cancer

  • Chaplin S
  • Payne H
Prescriber (2013) 24(22) 31-34
DOI: 10.1002/psb.1137
N/ACitations
Citations of this article
11Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Enzalutamide is a new second‐line treatment for castration‐resistant prostate cancer. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Dr Heather Payne discusses its place in treatment.

Cite

CITATION STYLE

APA

Chaplin, S., & Payne, H. (2013). Enzalutamide: new second‐line treatment for prostate cancer. Prescriber, 24(22), 31–34. https://doi.org/10.1002/psb.1137

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free